Toray Industries, Inc. - Product Pipeline Review - 2016
Summary
Global Markets Direct’s, ‘Toray Industries, Inc. - Product Pipeline Review - 2016’, provides an overview of the Toray Industries, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Toray Industries, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Toray Industries, Inc. - The report provides overview of Toray Industries, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Toray Industries, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Toray Industries, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Toray Industries, Inc.’s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Toray Industries, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Toray Industries, Inc.’s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
“Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Glucagon-Like Peptide 1 Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...
172 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Overactive Bladder (OAB) Therapeutics Market to Reach $3.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Overactive Bladder (OAB) Therapeutics estimated at US$3.2 Billion in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at aCAGR of 0.9%...
170 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Cartilage Repair/ Cartilage Regeneration Market to Reach $1.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Cartilage Repair/ Cartilage Regeneration estimated at US$592.3 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at aCAGR...
257 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Narcolepsy Therapeutics Market to Reach $3.8 Billion by 2027
- Amid the COVID-19 crisis, the global market for Narcolepsy Therapeutics estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$3.8 Billion by 2027, growing at a CAGR of 11.3% over the analysis period...
276 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Vaginitis Therapeutics Market to Reach $4.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Vaginitis Therapeutics estimated at US$2.7 Billion in the year 2020, is projected to reach a revised size of US$4.4 Billion by 2027, growing at a CAGR of 7.1% over the analysis period 2020-2027....
181 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Brain Tumor Therapeutics Market to Reach $3.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Brain Tumor Therapeutics estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$3.3 Billion by 2027, growing at aCAGR of 9.6% over the period 2020-2027....
125 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Non-Hodgkin Lymphoma Therapeutics Market to Reach $8.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Non-Hodgkin Lymphoma Therapeutics estimated at US$5.4 Billion in the year 2020, is projected to reach a revised size of US$8.1 Billion by 2027, growing at a CAGR of 6% over...
189 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Plasma Protein Therapeutics Market to Reach $32.8 Billion by 2027
- Amid the COVID-19 crisis, the global market for Plasma Protein Therapeutics estimated at US$24 Billion in the year 2020, is projected to reach a revised size of US$32.8 Billion by 2027, growing at a CAGR of 4.6% over the analysis...
120 pages •
By Infiniti Research Limited
• Mar 2021
Global Sjogrens Syndrome Therapeutics Market 2021-2025 The analyst has been monitoring the sjogrens syndrome therapeutics market and it is poised to grow by $ 287.68 mn during 2021-2025 progressing at a CAGR of 4% during the forecast period. Our report on sjogrens syndrome therapeutics market provides a holistic analysis,...